Chemistry:ML-007
ML-007 is a selective muscarinic acetylcholine M1 and M4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias.[1][2][3][4][5][6] It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC).[2][5][4] The drug is taken orally.[1]
It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test.[6] These effects appear to dependent on activation of both muscarinic acetylcholine M1 and M4 receptors.[6] The drug is approximately 10-fold more potent than xanomeline in these tests.[6]
As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias.[1][3][4] It is under development by MapLight Therapeutics.[1][3] The drug is a small molecule, but its chemical structure does not seem to have been disclosed.[5][1][3]
See also
- List of investigational antipsychotics
- Emraclidine
- NBI-1117568
- NS-136
- Xanomeline/trospium (KarXT)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "ML 007". AdisInsight. Springer Nature Switzerland AG. 9 January 2024. https://adisinsight.springer.com/drugs/800062983.
- ↑ 2.0 2.1 "ML 007/muscarinic antagonist". 8 May 2026. https://adisinsight.springer.com/drugs/800075149.
- ↑ 3.0 3.1 3.2 3.3 "Delving into the Latest Updates on ML-007 with Synapse". 19 September 2024. https://synapse.patsnap.com/drug/b28f987442e14a1b9abeed7005e6dbff.
- ↑ 4.0 4.1 4.2 "The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia". Frontiers in Psychiatry (Frontiers Media SA) 15. 4 October 2024. doi:10.3389/fpsyt.2024.1421554. ISSN 1664-0640. PMID 39483736.
- ↑ 5.0 5.1 5.2 "Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development". British Journal of Pharmacology 181 (22): 4385–4398. November 2024. doi:10.1111/bph.16081. PMID 37005377.
- ↑ 6.0 6.1 6.2 6.3 "Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M1 and M4 receptors". Neuropsychopharmacology 51 (5): 840–845. April 2026. doi:10.1038/s41386-025-02256-3. PMID 41046244.
 |  |
